TrialAnnals of internal medicine2024

A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.

Catharine I Paules et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.